October 25, 2018 A regimen showed favorable minimal residual disease negativity in patients with high-risk CLL, allowing many to pursue transplantation. A phase 2 clinical trial showed that ofatumumab with methylprednisolone followed by ofatumumab with…
Commission Calls for Integration of Oncology and Palliative…
October 26, 2018 A recent Lancet Oncology Commission laid out why oncology and palliative care should be integrated and how to achieve successful integration despite barriers. A Lancet Oncology Commission laid out why oncology and…
Efforts Made in the 1960s to Curb Smoking…
October 29, 2018 Scientific models project a continued decrease in lung cancer mortality. Tobacco control efforts implemented in the mid-1960s should continue to reduce lung cancer rates and mortality until 2065, according to a study…
Radiotherapy Did Not Improve Survival in All Patients…
October 29, 2018 Radiotherapy may improve survival among men with low metastatic burden. Adding radiotherapy to standard-of-care androgen deprivation therapy (ADT) did not improve survival in men with newly diagnosed metastatic prostate cancer, according to…
Bladder Cancer Risk Higher With Radiation Therapy for…
October 11, 2018 This article originally appeared on Renal and Urology News. In a recently published study, external beam radiation therapy for localized prostate cancer was associated with a 35% increased risk of bladder cancer…
Native Puerto Ricans Are at Increased Risk for…
October 11, 2018 Hispanics have a 25% lower cancer incidence rate compared with NHWs, but Puerto Ricans are subject to a higher occurrence of infection‐related cancers. Men living in Puerto Rico, a territory of the…
Radiotherapy Did Not Improve Survival in All Patients…
October 29, 2018 Radiotherapy may improve survival among men with low metastatic burden. Adding radiotherapy to standard-of-care androgen deprivation therapy (ADT) did not improve survival in men with newly diagnosed metastatic prostate cancer, according to…
Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative…
October 20, 2018 The drug combination was particularly beneficial for patients in the PD-L1–positive subgroup. Atezolizumab plus nab-paclitaxel significantly prolonged progression-free survival (PFS) among patients with metastatic triple-negative breast cancer, with an even greater benefit…
Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000…
October 20, 2018 Six months of treatment with trastuzumab is substantially more cost-effective than 12 months of therapy. Reducing the duration of trastuzumab to 6 months for the treatment of HER2-positive early breast cancer is…